STERIS (STE) Earnings Date & Reports
Steris is an Ireland-domiciled medical technology company focused on sterilization services and infection prevention... Show more
STE is expected to report earnings to fall 11.66% to $2.50 per share on August 10
STERIS plc (STE) Fiscal 2026 Fourth Quarter Earnings Recap: Solid Execution Amid Headwinds
Key Takeaways
- STERIS reported Q4 revenue from continuing operations of $1.6 billion, up 7% year-over-year, slightly above consensus estimates of $1.59 billion.
- Adjusted EPS came in at $2.83, beating consensus expectations of $2.89 and up from $2.74 last year.
- Full-year revenue reached $5.9 billion, a 9% increase, with constant currency organic growth of 7%.
- Full-year adjusted EPS of $10.17 hit the midpoint of company guidance ($10.15-$10.30).
- Free cash flow for FY2026 surged 25% to $982.9 million, exceeding prior outlook.
- FY2027 guidance calls for 7-8% revenue growth and adjusted EPS of $11.10-$11.30.
Earnings Context and Why It Matters
STERIS plc (STE), a leader in infection prevention and sterilization solutions, wrapped up fiscal 2026 with results that underscore its resilience in a challenging environment marked by tariffs and supply chain pressures. The quarter ended March 31, 2026, caps a year of consistent execution across its Healthcare, Applied Sterilization Technologies (AST), and Life Sciences segments. Investors watch these reports closely as they signal demand for procedural products amid rising healthcare volumes and regulatory focus on compliance. Strong free cash flow generation supports capital returns, including a new $1 billion share repurchase program, while forward guidance provides visibility into growth amid macroeconomic uncertainties.
STERIS delivered Q4 revenue from continuing operations of $1.6 billion, a 7% increase from $1.5 billion in the prior-year quarter, aligning closely with analyst consensus of approximately $1.59-$1.60 billion. Constant currency organic growth was 5%, driven by volume and pricing in services and consumables.
Adjusted diluted EPS reached $2.83, surpassing consensus estimates of $2.89 and improving 3% from $2.74 year-over-year. As-reported diluted EPS was $2.24, up from $1.48. Segment highlights included Healthcare revenue up 7% to $1.14 billion (organic 6%), AST up 6% to $289.2 million (organic 2%), and Life Sciences up 9% to $162.9 million (organic 6%).
For the full year, revenue grew 9% to $5.9 billion (organic 7%), and adjusted EPS rose 10% to $10.17, meeting the company's prior guidance midpoint despite $55 million in tariff impacts. Free cash flow hit a record $982.9 million, up from $787.2 million.
AI Screener
Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore it today to streamline your research process.
Market Reaction and Investor Sentiment
STERIS shares have traded volatile around recent earnings, with Q3 FY2026 results (reported February 4, 2026) triggering a 7.7% decline despite in-line EPS of $2.53 and 9% revenue growth, as investors weighed tariff headwinds. Historically, STE stock moves about 53% positively post-earnings over five years, with median gains of 6% on beats. Q4's EPS beat and raised FY2027 outlook likely bolstered sentiment, though modest revenue and organic growth trailed some expectations, tempering gains.
Forward Outlook and Key Factors to Monitor
STERIS issued FY2027 guidance projecting 7-8% as-reported revenue growth (6-7% constant currency organic) and adjusted EPS of $11.10-$11.30, implying 9-11% growth from FY2026's $10.17. This outlook incorporates ongoing tariff pressures but assumes stable procedure volumes and pricing discipline.
Investors should track segment dynamics: Healthcare services and consumables remain resilient, but AST capital equipment softness and Life Sciences competition warrant attention. Free cash flow guidance of ~$850 million supports dividends and the new $1 billion buyback, enhancing shareholder returns.
Broader factors include U.S. healthcare spending trends, supply chain stabilization, and tariff resolutions. CEO Dan Carestio emphasized procedural growth and customer focus as drivers. Upcoming catalysts: Q1 FY2027 earnings in August and Analyst Day insights.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
Advertisement
General Information
a manufacturer of surgical and other medical supplies
Industry MedicalNursingServices